Skip to main content
. 2016 Apr 21;11(4):e0153975. doi: 10.1371/journal.pone.0153975

Fig 1. Relapse and survival following ingenol mebutate treatment of B16 tumours grown in MyD88-/- and C57BL/6 mice.

Fig 1

(A) Relapse rates following (i) ingenol mebutate treatment of B16 tumours grown in MyD88-/- mice (n = 25), (ii) ingenol mebutate treatment of B16 tumours grown in C57BL/6 mice (n = 21), (iii) placebo treatment of B16 tumours grown in MyD88-/- mice (n = 18) and (iv) placebo treatment of B16 tumours grown in C57BL/6 mice (n = 19). Mice were scored positive when a tumour was clearly visible (≥1–2 mm in diameter). Data from two independent experiments. Ingenol mebutate treatment groups were significantly different p = 0.021, log-rank (Mantel-Cox) test. (B) Survival rates of the same mice described in A; mice were euthanized when tumours reached 100 mm2. Ingenol mebutate treatment groups were significantly different p = 0.018, log-rank (Mantel-Cox) test.